Does RISANKIZUMAB-RZAA Cause Bladder cancer recurrent? 10 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Bladder cancer recurrent have been filed in association with RISANKIZUMAB-RZAA. This represents 0.0% of all adverse event reports for RISANKIZUMAB-RZAA.
10
Reports of Bladder cancer recurrent with RISANKIZUMAB-RZAA
0.0%
of all RISANKIZUMAB-RZAA reports
0
Deaths
1
Hospitalizations
How Dangerous Is Bladder cancer recurrent From RISANKIZUMAB-RZAA?
Of the 10 reports, 1 (10.0%) required hospitalization.
Is Bladder cancer recurrent Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB-RZAA. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does RISANKIZUMAB-RZAA Cause?
Psoriasis (6,896)
Drug ineffective (2,885)
Pain (2,584)
Fatigue (2,483)
Arthralgia (2,419)
Pruritus (2,311)
Covid-19 (2,145)
Death (1,700)
Fall (1,666)
Surgery (1,662)
What Other Drugs Cause Bladder cancer recurrent?
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (231)
PIOGLITAZONE (130)
RANITIDINE (66)
BACILLUS CALMETTE-GUERIN ANTIGEN, UNSPECIFIED SUBSTRAIN (28)
MITOMYCIN (20)
PEMBROLIZUMAB (20)
ADALIMUMAB (19)
GEMCITABINE\GEMCITABINE (19)
METHOTREXATE (16)
GEMCITABINE (15)
Which RISANKIZUMAB-RZAA Alternatives Have Lower Bladder cancer recurrent Risk?
RISANKIZUMAB-RZAA vs RISDIPLAM
RISANKIZUMAB-RZAA vs RISEDRONATE
RISANKIZUMAB-RZAA vs RISEDRONIC ACID
RISANKIZUMAB-RZAA vs RISPERDAL
RISANKIZUMAB-RZAA vs RISPERDAL CONSTA